Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.

Chung-Han Lee,Martin H. Voss,Maria I. Carlo,Ying-Bei Chen,Eduard Reznik,Andrea Knezevic,Robert A. Lefkowitz,Natalie Shapnik,Diana Tassone,Chloe Dadoun,Neil J. Shah,Colette Owens,Deaglan Joseph McHugh,David H. Aggen,Andrew L. Laccetti,Ritesh Kotecha,Darren R. Feldman,Robert J. Motzer

Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.

2021

Chung-Han Lee
Martin H. Voss
Maria I. Carlo
Ying-Bei Chen
Eduard Reznik
Andrea Knezevic
Robert A. Lefkowitz
Natalie Shapnik
Diana Tassone
Chloe Dadoun
Neil J. Shah
Colette Owens
Deaglan Joseph McHugh
David H. Aggen
Andrew L. Laccetti
Ritesh Kotecha
Darren R. Feldman
Robert J. Motzer

4509Background: Cabozantinib plus nivolumab (CaboNivo) improved objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) over sunitinib in a phase 3 trial for metas...

Keywords:

Nivolumab
Internal medicine
Medicine
objective response
Oncology
overall survival
in patient
Cabozantinib
Sunitinib
Clear cell renal cell carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations